Keywords: OPKO Health, Cytochroma, M&A, Replidea, Alpharen, Hyperparathyroidism, Hyperphosphatemia

OPKO Health inks deal to acquire Cytochroma and two Ph III products

Article | 10 January 2013

Print This

Privately-held Canadian company Cytochroma says that it has entered into a definitive agreement to be acquired by USA-based OPKO Health ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in